Marylore Chenel, Ph.D.

Chief Research Officer

Portrait-of-Marylore-Chenel_Pharmetheus

Bio

  • Joined Pharmetheus in 2021, serving as Chief Research Officer, part of the executive leadership team, and leading the PBPK-QSP Business Development Platform
  • Expertise includes model-informed drug development, clinical pharmacology and regulatory advices in therapeutic areas such as oncology/immuno-oncology, immuno-inflammation, cardiology, and diabetes
  • Previously worked as Head of Global Pharmacometrics and Clinical Pharmacokinetics at Servier, France, where she led a team supporting the drug development portfolio from research to submission including lifecycle management, as Head and Deputy Head of Clinical Pharmacometrics and Clinical Pharmacokinetics, as a Pharmacometrician at Servier, France, and as Postdoctoral Fellow at the University of Manchester, UK
  • PharmD (2000) and M.Sc. in Pharmacokinetics (2000) from the University of Paris V, France, and Ph.D in Pharmacokinetics – PKPD modeling from the University of Poitiers, France
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Pharmacokinetic-target engagement modelling of an anti-CCL17 monoclonal antibody in healthy volunteers and osteoarthritis patientsPhysiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcomaModel-based approach for a new Prolonged-Release (PR) formulation of ivabradine: PK and PKPD assessment to support bioequivalencePhysiologically based predictions of monoclonal antibody pharmacokinetics: insights from a large-scale data analysisHarnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community ConferenceModel-informed drug development of flucytosine sustained release formulation in the treatment of cryptococcal meningitis: A case study using PBPK modelingPhysiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case studyPhase 1 interim population PK/PD modeling and recommended phase 2 dose exploration for IMM-1-104: A novel concept oral deep cyclic inhibitor of MEKA quantitative systems pharmacology framework of immunogenicity to propose mitigation strategies after subcutaneous administrationOptimizing Formulations for Treatment of Cryptococcal Meningoencephalitis in Sub-Saharan HIV Patients: Insights from PBPK ModelingBioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitis